908 Devices Inc. Income Taxes Disclosure
12. Income Taxes
Loss before income taxes for continuing operations for the years ended December 31, 2025 and 2024 consisted of the following (in thousands):
December 31, | ||||||
2025 | | 2024 | ||||
Domestic | $ | (33,343) | $ | (53,140) | ||
Foreign | — | — | ||||
$ | (33,343) | $ | (53,140) | |||
The provision for income taxes for the years ended December 31, 2025 and 2024 consisted of the following (in thousands):
December 31, | ||||||
2025 | | 2024 | ||||
Current tax expense (benefit): | ||||||
Federal | $ | — | $ | — | ||
State | 48 | — | ||||
Foreign | (114) | — | ||||
(66) | — | |||||
Deferred tax expense (benefit): | ||||||
Federal | — | — | ||||
State | — | — | ||||
Foreign | — | — | ||||
Total tax benefit | $ | (66) | $ | — | ||
As further described in Note 2, Summary of Significant Accounting Policies, we have elected to prospectively adopt the guidance in ASU 2023-09. The following table is a reconciliation of our effective income tax rate to the statutory federal income tax rate for the year ended December 31, 2025 in accordance with the guidance in ASU 2023-09:
| Year Ended December 31, | |||||
2025 | ||||||
Amount | Percent | |||||
Federal statutory income tax rate |
| $ | (7,002) | (21.0) | % | |
| 38 | 0.1 |
| |||
Foreign tax effects |
| (113) | (0.3) |
| ||
Tax credits - research and development tax credits |
| (444) | (1.3) |
| ||
Change in valuation allowance |
| 6,234 | 18.7 |
| ||
Nontaxable or nondeductible items |
|
| ||||
Shortfall on stock option exercises | 1,032 | 3.1 | ||||
Other | 108 | 0.3 | ||||
Other | 81 | 0.2 | ||||
Effective income tax rate |
| $ | (66) | (0.2) | % | |
| (1) | State taxes in Massachusetts and California made up the majority (greater than 50 percent) of the tax effect in this category. |
A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate for the year ended December 31, 2024, prior to our adoption of ASU 2023-09, is as follows:
Year Ended December 31, | |||
2024 | |||
Federal statutory income tax rate |
| (21.0) | % |
State income taxes, net of federal benefit |
| (3.0) |
|
Federal and state research and development tax credits |
| (2.7) |
|
Nondeductible items |
| 4.4 |
|
Change in valuation allowance |
| 22.1 |
|
Effective income tax rate |
| (0.2) | % |
Income taxes paid, net of refund received, for the continuing operations during the years ended December 31, 2025 consisted of the following (in thousands):
December 31, | |||
2025 | |||
U.S. Federal income taxes | $ | — | |
U.S. state and local income taxes: | 49 | ||
Foreign countries | |||
Germany | (115) | ||
Total income taxes refund | $ | (66) | |
There were no income taxes paid for the continuing operations during the years ended December 31, 2024.
Significant components of our deferred tax assets and liabilities consisted of the following (in thousands):
| December 31, | |||||
2025 | | 2024 | ||||
Deferred tax assets: |
| | | |||
Net operating loss carryforwards | $ | 36,327 | $ | 32,162 | ||
Tax credit carryforwards |
| 13,039 |
| 12,509 | ||
Lease liability |
| 1,114 |
| 1,571 | ||
Deferred Revenue |
| 2,478 |
| 2,234 | ||
Amortization | 7,616 | 4,658 | ||||
Accrued expenses and other |
| 5,568 |
| 7,033 | ||
Capitalization under Section 174(a) |
| 377 |
| 10,295 | ||
Total deferred tax assets |
| 66,519 |
| 70,462 | ||
Deferred tax liabilities: |
| |
| | ||
Right-of-use asset |
| (1,058) |
| (1,646) | ||
Total deferred tax liabilities |
| (1,058) |
| (1,646) | ||
Valuation allowance |
| (65,461) |
| (68,816) | ||
Net deferred tax liabilities | $ | — | $ | — | ||
As of December 31, 2025, the Company had gross federal and state operating loss carryforwards of $147.0 million and $94.5 million, respectively. The federal operating loss carryforward may be available to offset future taxable income and begin to expire in 2032, of which $112.6 million of federal gross operating losses do not expire. As of December 31, 2025, the Company also had U.S. federal and state research and development tax credit carryforwards of $9.1 million and $4.9 million, respectively, which may be available to offset future tax liabilities and begin to expire in 2032 and 2030, respectively.
Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period.
The Company conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception through March 31, 2025 and has determined that two historic ownership changes have occurred as defined by Section 382. Both ownership changes are not expected to have a material impact to the Company’s net operating loss carryforwards or research and development tax credit carryforwards as these net
operating losses and tax credit carryforwards may be utilized, subject to annual limitation, assuming sufficient taxable income is generated before expiration.
The Company has not conducted a study to document qualified activities for research and development tax credits generated. Such a study may result in an adjustment to the Company’s research and development tax credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position.
The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company’s history of cumulative net operating losses incurred since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, as of December 31, 2025 and 2024, a full valuation allowance has been established against the net deferred tax assets, except for deferred tax liabilities recorded under our foreign jurisdiction, which amounted to none and $2.0 million as of December 31, 2025 and 2024, respectively.
Changes in the valuation allowance for deferred tax assets related primarily to the change in capitalization under Section 174(a) and net operating loss carryforwards and were as follows (in thousands):
| Year Ended December 31, | |||||
2025 | | 2024 | ||||
Valuation allowance as of beginning of year | $ | 68,816 | $ | 52,825 | ||
(Decreases) increases recorded to income tax provision |
| (3,355) |
| 15,991 | ||
Valuation allowance as of end of year | $ | 65,461 | $ | 68,816 | ||
As of December 31, 2025 and 2024, the Company had not recorded any amounts for unrecognized tax benefits. The Company’s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of December 31, 2025 and 2024, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts had been recognized in the Company’s consolidated statements of operations. The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company is open to future tax examination under statute from 2020 to the present; however, carryforward attributes that were generated prior to 2020 may still be adjusted upon examination by federal, state, or local tax authorities if they either have been or will be used in a future period. The Company has not received notice of examination by any other jurisdictions for any other tax year open under statute.
On July 4, 2025, the United States Congress passed budget reconciliation bill H.R. 1 referred to as the One Big Beautiful Bill (“OBBB”). The OBBB contains several changes to corporate taxation including modifications to capitalization of research and development expenses, limitations on deductions for interest expense and accelerated fixed asset depreciation. While the Company continues to assess the impact of the tax provisions of the OBBB on our consolidated financial statements, the Company currently believes that the tax provisions of the legislation are not expected to have a material impact on its operations. The impacts of the OBBB are not material to the 2025 consolidated financial statements; however, impacts to future periods will continue to be evaluated.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 9, 2026 | Showing above |
| 2024 | Mar 7, 2025 | |
| 2023 | Mar 8, 2024 | |
| 2022 | Mar 15, 2023 | |
| 2021 | Mar 11, 2022 | |
About Income Taxes Disclosures
The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.
Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.